000 04002nam a22005655i 4500
001 978-3-211-88893-3
003 DE-He213
005 20140220084518.0
007 cr nn 008mamaa
008 100301s2010 au | s |||| 0|eng d
020 _a9783211888933
_9978-3-211-88893-3
024 7 _a10.1007/978-3-211-88893-3
_2doi
050 4 _aRC254-282
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
082 0 4 _a616.994
_223
100 1 _aMader, Ines.
_eauthor.
245 1 0 _aExtravasation of Cytotoxic Agents
_h[electronic resource] :
_bCompendium for Prevention and Management /
_cby Ines Mader, Patrizia Fürst-Weger, Robert Mader, Elisabeth Nogler-Semenitz, Sabine Wassertheurer.
250 _a2.
264 1 _aVienna :
_bSpringer Vienna :
_bImprint: Springer,
_c2010.
300 _aXIII, 394 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aProblem outline -- Problem outline -- General part -- and definitions -- Predisposition and prevention -- Clinical practice -- Measures -- Aftercare -- Documentation -- Forming clinical working groups -- Quality control and quality assurance -- Open questions and outlook -- Substance-specific part -- Remarks on the substance-specific part -- Amsacrine -- L-Asparaginase -- Bendamustine -- Bleomycin -- Bortezomib -- Busulfan -- Carboplatin -- Carmustine -- Cisplatin -- Cladribine -- Cyclophosphamide -- Cytarabine -- Dacarbazine -- Dactinomycin -- Daunorubicin -- Daunorubicin liposomal -- Docetaxel -- Doxorubicin -- Doxorubicin liposomal, Doxorubicin pegylated liposomal -- Epirubicin -- Estramustine -- Etoposide -- Etoposide phosphate -- Fludarabine -- 5-Fluorouracil -- Fotemustine -- Gemcitabine -- Idarubicin -- Ifosfamide -- Irinotecan -- Melphalan -- Methotrexate -- Mitomycin C -- Mitoxantrone -- Nimustine -- Oxaliplatin -- Paclitaxel -- Pegaspargase -- Pemetrexed -- Pentostatin -- Raltitrexed -- Streptozocin -- Teniposide -- Thiotepa -- Topotecan -- Treosulfan -- Trimetrexate -- Vinblastine -- Vincristine -- Vindesine -- Vinorelbine.
520 _aThe extravasation of cytotoxic agents can result in severe local tissue damage and medical emergencies during tumour therapy. This revised compendium is intended to help clinicians assess any situation speedily and with certainty. The general section of the book includes topics such as predisposition, prevention, type of harm, general measures in handling extravasated drugs, specific antidotes, and documentation. In the 2nd edition, the scientific information contained in the general section and relating to the actual substances has been updated. The substance specific part of the book includes detailed instructions on handling more than 50 cytotoxic drugs, to initiate targeted measures. Templates for an extravasation set, overview tables, documentation sheets, and patient information, as we as a CD-ROM are included to support clinical practice. The book is the outcome of a consensus of an interdisciplinary working group that has collected and systematically reviewed all published literature on the topic.
650 0 _aMedicine.
650 0 _aToxicology.
650 0 _aInternal medicine.
650 0 _aHematology.
650 0 _aNursing.
650 0 _aOncology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aOncology.
650 2 4 _aHematology.
650 2 4 _aNursing.
650 2 4 _aPharmacology/Toxicology.
650 2 4 _aInternal Medicine.
700 1 _aFürst-Weger, Patrizia.
_eauthor.
700 1 _aMader, Robert.
_eauthor.
700 1 _aNogler-Semenitz, Elisabeth.
_eauthor.
700 1 _aWassertheurer, Sabine.
_eauthor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783211888896
856 4 0 _uhttp://dx.doi.org/10.1007/978-3-211-88893-3
912 _aZDB-2-SME
999 _c111133
_d111133